InnoCare secures Chinese IND clearance for its first bispecific ADC, ICP‑B381, targeting PSMA and STEAP1, marking a new clinical‑stage asset in the fast‑growing Chinese oncology pipeline
Executive summary: InnoCare received IND approval from China's NMPA to start a clinical trial of ICP‑B381, a bispecific ADC targeting PSMA and STEAP1, its first bispecific ADC and third ADC overall to reach the clinic. The clearance adds a novel bispecific ADC to China's oncology pipeline, potentially addressing prostate and other PSMA/STEAP1‑expressing cancers and signaling regulatory openness to complex bioconjugates.
Who is involved: InnoCare (Chinese biotech), China NMPA (regulator), clinical investigators in China; the asset targets PSMA and STEAP1, both validated oncology antigens.
Likely next: Initiation of patient dosing, disclosure of trial design (phase, endpoints, sites), and early safety/pharmacokinetic readouts within the next 12‑18 months.
InnoCare announced that China's National Medical Products Administration has approved the clinical trial of ICP‑B381, a bispecific antibody‑drug conjugate aimed at prostate‑specific membrane antigen and STEAP1. This is the company's third ADC to enter the clinic and the first bispecific format, expanding its oncology portfolio beyond single‑target ADCs. The approval reflects China's accelerating support for innovative biologics and positions InnoCare to compete with global ADC developers in a high‑value solid‑tumor indication. The trial's design and timeline have not been disclosed, so the near‑term impact hinges on patient enrollment speed and early safety signals.
What's next — scenarios
Base: trial launches on schedule, early data in 2027 (55%)
InnoCare advances a differentiated bispecific ADC, attracting potential partnership interest and supporting valuation.
- First patient dosed by Q4 2026
- No clinical hold from NMPA after safety review
- Competitor bispecific ADC data (e.g., from global pharma) remains mixed
Upside: rapid enrollment and promising Phase I efficacy signals (25%)
Accelerated development timeline, possible fast‑track designation, and heightened M&A interest from global ADC players.
- Enrollment of ≥30 patients within 6 months
- Objective response rate ≥30% in heavily pre‑treated prostate cancer cohort
- Positive DSMB recommendation to expand cohort
Downside: safety concerns or regulatory delay stall the program (20%)
Program timeline extends 12‑24 months, cash burn rises, and investor confidence wanes.
- Grade ≥3 off‑target toxicity in ≥2 patients
- NMPA issues a clinical hold pending additional CMC data
- Manufacturing yield issues for the bispecific construct
What to watch
- First‑patient‑dosed announcement (expected Q4 2026)
- NMPA safety review outcome after initial cohort (Q1 2027)
- Publication of trial design details on ClinicalTrials.gov
- Competitor bispecific ADC readouts (e.g., from Roche, AstraZeneca) in 2026‑2027
- InnoCare cash‑flow updates in quarterly filings (next report due Nov 2026)
Timeline
- — InnoCare Announces Approval of Clinical Trial of Novel Bispecific ADC ICP-B381 Targeting PSMA/ STEAP1 in China (GlobeNewswire)
- — Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums (GlobeNewswire)
Analysis — what this means
Likely next events
- First patient dosed by end of 2026
- Initial safety data release Q1 2027
- Potential IND amendment for dose escalation Q2 2027
Sectors affected
- Biopharmaceuticals – antibody‑drug conjugates
- Oncology – prostate and solid‑tumor targeted therapies
- Chinese biotech innovation ecosystem
Regulatory implications
- NMPA's willingness to approve bispecific ADC INDs may set precedent for other complex biologics
- Compliance with China's new drug registration reforms (2025) for innovative biologics
Historical parallels
- First Chinese bispecific ADC IND (e.g., BeiGene's BGB‑101, 2023) – led to partnership with Novartis
- Global first bispecific ADC (Genentech's RG7891, 2015) – demonstrated feasibility but faced manufacturing hurdles
Key entities
Sources
- InnoCare Announces Approval of Clinical Trial of Novel Bispecific ADC ICP-B381 Targeting PSMA/ STEAP1 in China — GlobeNewswire
- Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums — GlobeNewswire
Related cases
- Akeso’s 2026 interim results show record‑high drug sales and progress on its IO 2.0 strategy, advancing bispecific ADCs in oncology, immunology and Alzheimer’s
- Akeso's B7‑H3 ADC AK157D1 gains Phase I clearance, adding a third differentiated candidate to its oncology pipeline
- Henlius and Sandoz partner to co‑develop up to ten biosimilar mAb and ADC assets, aiming to accelerate global market access and revenue generation
- Akeso advances its IO2.0/ADC2.0 strategy with first patient dosed in Phase II trial of AK146D1 combined with ivonescimab for breast cancer
- GlycoNex initiates first-in-human Phase I trial of its glycan-targeted ADC GNX1021 in Japan
- Akeso initiates first‑in‑human trial of its HER3‑targeted ADC combined with Ivonescimab in lung cancer, advancing its IO2.0+ADC2.0 pipeline